Pharmacokinetic model selection for infliximab based on inflammatory bowel disease phenotype and severity: Toward model-informed precision dosing
PLOS One · 2026
DOI: 10.1371/journal.pone.0352967 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Ana Homšek Ilić und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacokinetics and Clinical Pharmacy, University of Belgrade - Faculty of Pharmacy, Belgrade, Republic of Serbia. Hauptthemen laut MEDLINE: Infliximab, Inflammatory Bowel Diseases, Models, Biological, Crohn Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Fund of the Republic of Serbia.
Abstract (Originalsprache)
Ulcerative colitis (UC) and Crohn’s disease (CD) differ in intestinal location and depth of involvement. Patients with UC who have or experienced a flare-up according to Truelove–Witts criteria (ACUS), as well as those with fistulizing Crohn’s disease (FIST), may represent difficult-to-treat populations. This study investigates the phenotype- and severity-driven selection of infliximab (IFX) population pharmacokinetic models to optimize predictive performance and support precision dosing in inflammatory bowel disease (IBD) care. A retrospective analysis was conducted at University Hospital Medical Centre “Zvezdara”. Twenty published IFX models were evaluated across five datasets (overall, ASUC, CD, FIST, UC), primarily using trough concentrations obtained via routine therapeutic drug monitoring. Predictive accuracy was assessed using median prediction error (MDPE) and median absolute prediction error (MAPE). Bayesian forecasts were evaluated using median individual prediction error (MDIPE) and its absolute value (MAIPE). Normalized prediction distribution errors (NPDE) and visual predictive check (VPC) were used for simulation-based diagnostics. Moreover, probability of probability of target-attainment (PTA%) per model and subgroup was calculated. No model met all predefined prediction-based performance criteria. In a priori analysis, the Matsuoka model showed the satisfactory overall performance, while the Xu model was most suitable for CD patients. In a posteriori analysis, the Ternant 2008 model had the well overall accuracy, with other models (Dreesen 2021 for ASUC, Matsuoka for CD, Brandse 2016 for UC) performing satisfactory in respective subgroups. Simulation NPDE diagnostics identified the Aubourg model as suitable for the overall dataset, while VPC results mainly supported the a priori analysis conclusions. These findings highlight the relevance of disease phenotype and severity in selecting IFX pharmacokinetic models. Rather than relying on a one-size-fits-all approach, tailoring model choice to patient subgroups enhances predictive performance. This supports a more individualized, model-informed precision dosing (MIPD) strategy for optimizing IFX dosing in IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacokinetics and Clinical Pharmacy, University of Belgrade - Faculty of Pharmacy, Belgrade, Republic of Serbia.
- University Hospital Medical Centre "Zvezdara", Department of Gastroenterology and Hepatology, Belgrade, Republic of Serbia.
- University of Belgrade - Faculty of Medicine, Belgrade, Republic of Serbia.
ORCID-Profile: Katarina Vučićević
Förderung
- Science Fund of the Republic of Serbia
Zitieren
APA
Homšek Ilić, A., Jovanović, M., Marković, S., Vezmar Kovačević, S., Knežević Ivanovski, T., Kralj, Đ., Svorcan, P., & Vučićević, K. (2026). Pharmacokinetic model selection for infliximab based on inflammatory bowel disease phenotype and severity: Toward model-informed precision dosing. PLOS One. https://doi.org/10.1371/journal.pone.0352967
Vancouver
Homšek Ilić A, Jovanović M, Marković S, Vezmar Kovačević S, Knežević Ivanovski T, Kralj Đ, et al. Pharmacokinetic model selection for infliximab based on inflammatory bowel disease phenotype and severity: Toward model-informed precision dosing. PLOS One. 2026. doi:10.1371/journal.pone.0352967
BibTeX
@article{HomekIli2026,
author = {Homšek Ilić, Ana and Jovanović, Marija and Marković, Srđan and Vezmar Kovačević, Sandra and Knežević Ivanovski, Tamara and Kralj, Đorđe and Svorcan, Petar and Vučićević, Katarina},
title = {Pharmacokinetic model selection for infliximab based on inflammatory bowel disease phenotype and severity: Toward model-informed precision dosing},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0352967}
}
EUVIMED